Abstract
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Current Medicinal Chemistry
Title: TRAIL: A Sword for Killing Tumors
Volume: 17 Issue: 29
Author(s): S. Wang
Affiliation:
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Export Options
About this article
Cite this article as:
Wang S., TRAIL: A Sword for Killing Tumors, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176285
DOI https://dx.doi.org/10.2174/092986710793176285 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Nutritional Values of Foxtail Millet (<i>Setaria italica</i>) and other Millets Used for Common Diseases and Management
Current Nutrition & Food Science Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets The Pharmacological Treatment of Cachexia
Current Drug Targets Liquid Chromatographic Analysis of Methotrexate and Minocycline-relevance to the Determination in Plasma/Nanoparticulate Formulations
Current Chromatography Accuracy of a Topical PET/CT Scanner on SUV Measurements of Small Volumes SUV
Current Medical Imaging Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design Preparation and Characterization of Highly Fluorescent TGA-CdTe Quantum Dot-Hyamine 1622 Additive Composite
Micro and Nanosystems Editorial (Thematic Issue: Gene Therapy for Fanconi Anemia Enters a New Clinical Era)
Current Gene Therapy Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Editorial (Thematic Issue: Targeted Anti-Cancer Drug Delivery)
Current Cancer Drug Targets Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets